Human mesenchymal stromal cells enhance the immunomodulatory function of CD8+ CD28- regulatory T cells

Cellular and Molecular Immunology

Volumn 12, Issue 6, 2015, Pages 708-718

  Liu, Qiuli ^a   Zheng, Haiqing ^a   Chen, Xiaoyong ^a   Peng, Yanwen ^a   Huang, Weijun ^a   Li, Xiaobo ^a   Li, Gang ^a   Xia, Wenjie ^b   Sun, Qiquan ^a   Xiang, Andy Peng ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangzhou Blood Centre   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

antigens; CD28; CD8 positive T cells; mesenchymal stromal cells; regulatory T cells

Indexed keywords

CD28 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; FASLG PROTEIN, HUMAN; IL10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ CD28+ REGULATORY T LYMPHOCYTE; CD8+ CD28- REGULATORY T LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ADIPOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; OSTEOBLAST; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

ADIPOCYTES; ANTIGENS, CD28; ANTIGENS, CD8; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOMODULATION; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84946010892     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.118     Document Type: Article

References (50)

1. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119: 2204-2213.
2. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010; 20: 510-518.
3. Shi M, Liu ZW, Wang FS. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 2011; 164: 1-8.
4. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. Vox Sang 2010; 98: 93-107.
5. Lin H, Xu R, Zhang Z, Chen L, Shi M, Wang FS. Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cell Mol Immunol 2011; 8: 19-22.
6. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-397.
7. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
8. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010; 5: e14247.
9. Sakaguchi S. Naturally arising CD41 regulatory t cells for immunologic self-Tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562.
10. Di Ianni M, del Papa B, de Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36: 309-318.
11. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD41CD25High forkhead box P31 regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
12. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD41 or CD81 regulatory T cells upon mesenchymal stem celllymphocyte interaction. Haematologica 2007; 92: 881-888.
13. Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le Blanc K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011; 117: 4826-4835.
14. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212: 28-50.
15. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151.
16. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD81 T cells. Blood 2003; 101: 2711-2720.
17. Arosa FA. CD81CD282 T cells: certainties and uncertainties of a prevalent human T-cell subset. Immunol Cell Biol 2002; 80: 1-13.
18. Merino J, Martinez-Gonzalez MA, Rubio M, Inoges S, Sanchez-Ibarrola A, Subira ML. Progressive decrease of CD8high1 CD281 CD572 cells with ageing. Clin Exp Immunol 1998; 112: 48-51.
19. Weng NP, Akbar AN, Goronzy J. CD282 T cells: their role in the ageassociated decline of immune function. Trends Immunol 2009; 30: 306-312.
20. Mikulkova Z, Praksova P, Stourac P, Bednarik J, Strajtova L, Pacasova R, et al. Numerical defects in CD81CD282 T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol 2010; 262: 75-79.
21. Tulunay A, Yavuz S, Direskeneli H, Eksioglu-Demiralp E. CD81CD282, suppressive T cells in systemic lupus erythematosus. Lupus 2008; 17: 630-637.
22. Sun Z, Zhong W, Lu X, Shi B, Zhu Y, Chen L, et al. Association of Graves disease and prevalence of circulating IFN-gammaproducing CD282 T cells. J Clin Immunol 2008; 28: 464-472.
23. Scarsi M, Ziglioli T, Airo P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 2010; 37: 911-916.
24. Lin YX, Wang LL, Yan LN, Cai P, Li B, Wen TF, et al. Analysis of CD81CD282 T-suppressor cells in living donor liver transplant recipients. Hepatobiliary Pancreat Dis Int 2009; 8: 241-246.
25. Klaus G, Mostert K, Reckzeh B, Mueller TF. Phenotypic changes in lymphocyte subpopulations in pediatric renal-Transplant patients after T-cell depletion. Transplantation 2003; 76: 1719-1724.
26. Hof-Nahor I, Leshansky L, Shivtiel S, Eldor L, Aberdam D, Itskovitz-Eldor J, et al. Human mesenchymal stem cells shift CD81 T cells towards a suppressive phenotype by inducing tolerogenic monocytes. J Cell Sci 2012; 125: 4640-4650.
27. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010; 45: 1732-1740.
28. Peng Y, Chen X, Liu Q, Zhang X, Huang K, Liu L, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD51 regulatory B cells producing interleukin 10. Leukemia 2014; in press
29. Engela AU, Baan CC, Litjens NH, Franquesa M, Betjes MG, Weimar W, et al. Mesenchymal stem cells control alloreactive CD81 CD282 T cells. Clin Exp Immunol 2013; 174: 449-458.
30. Wang R, Shi YF. A simplified protocol for apoptosis assay by DNA content analysis. Biotechniques 2002; Suppl: 88-91.
31. Menager-Marcq I, Pomie C, Romagnoli P, van Meerwijk JP. CD81CD282 regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology 2006; 131: 1775-1785.
32. Levings MK, Sangregorio R, Roncarolo MG. Human CD251CD41 T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-1302.
33. Johannisson A, Thuvander A, Gadhasson IL. Activation markers and cell proliferation as indicators of toxicity: a flow cytometric approach. Cell Biol Toxicol 1995; 11: 355-366.
34. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD41CD251Foxp31 regulatory T cells induce cytokine deprivationmediated apoptosis of effector CD41 T cells. Nat Immunol 2007; 8: 1353-1362.
35. Gu YZ, Xue Q, Chen YJ, Yu GH, Qing MD, Shen Y, et al. Different roles of PD-L1 and FasL in immunomodulation mediated by human placentaderived mesenchymal stem cells. Hum Immunol 2013; 74: 267-276.
36. Nagata S. Fas-mediated apoptosis. Adv Exp Med Biol 1996; 406: 119-124.
37. Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, et al. CD81 CD282 T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179: 4323-4334.
38. Colovai AI, Mirza M, Vlad G, Wang S, Ho E, Cortesini R, et al. Regulatory CD81CD282 T cells in heart transplant recipients. Hum Immunol 2003; 64: 31-37.
39. Ceeraz S, Hall C, Choy EH, Spencer J, Corrigall VM. Defective CD81 CD282 regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clin Exp Immunol 2013; 174: 18-26.
40. Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? Immunol Cell Biol 2013; 91: 12-18.
41. Ni Choileain N, MacConmara M, Zang Y, Murphy TJ, Mannick JA, Lederer JA. Enhanced regulatory T cell activity is an element of the host response to injury. J Immunol 2006; 176: 225-236.
42. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
43. Ren X, Ye F, Jiang Z, Chu Y, Xiong S, Wang Y. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD41CD251 regulatory T cells. Cell Death Differ 2007; 14: 2076-2084.
44. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp31 regulatory T cell function. Science 2008; 322: 271-275.
45. Zhang W, Ge W, Li CH, You SG, Han Q, Deng WM, et al. [Inhibition effect of bone marrow mesenchymal stem cells on T-lymphocyte proliferation through up-regulation of CD81CD282 T cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004; 12: 666-669. Chinese
46. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 2005; 205: 158-169.
47. Strioga M, Pasukoniene V, Characiejus D. CD81 CD282 and CD81 CD571 T cells and their role in health and disease. Immunology 2011; 134: 17-32.
48. Xu G, Zhang Y, Zhang L, Ren G, Shi Y. The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells. Biochem Biophys Res Commun 2007; 361: 745-750.
49. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol 1997; 158: 5791-5796.
50. Ayroldi E, Zollo O, Cannarile L, DAdamio F, Grohmann U, Delfino DV, et al. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death. Blood 1998; 92: 4212-4219.